Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Link between Abdominal Obesity Indices and the Progression of Liver Fibrosis, Insights from a Population-Based Study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Arteaga, Ingrid
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Ruiz-Rojano, Irene
  • Casademunt-Gras, Elena
  • Chacón, Carla|||0000-0001-8524-6189
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
There is currently no available information on the correlation between abdominal obesity indices and the risk of liver fibrosis progression. We aimed to investigate the relationship between the body mass index (BMI), waist circumference (WC), and the visceral adiposity index (VAI) with the progression of liver fibrosis. The study also evaluated the association between these indices and the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis. A total of 1403 subjects participated in the cross-sectional and longitudinal population-based study. Liver stiffness was assessed via transient elastography, at baseline and follow-up (median: 4.2 years). The subgroup with dysglycemia was also analyzed. In the cross-sectional study, the highest quartile of VAI, BMI ≥ 30 kg/m 2, and abdominal obesity showed significant associations with the prevalence of MASLD and liver fibrosis, as well as with fibrosis progression. However, VAI showed no association with MASLD incidence. Among the dysglycemic subjects, there was no observed association between VAI and the incidence of MASLD or the progression of fibrosis. In conclusion, the BMI, WC, and the VAI are associated with an increased risk of progression to moderate-to-advanced liver fibrosis in the general population. However, the VAI does not perform better than the BMI and WC measurement.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects, A population-based study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Ballesta Purroy, Sílvia|||0000-0001-8057-1804
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Expósito, Carmen|||0000-0002-9246-3779
  • Martinez Escude, Alba|||0000-0003-0667-1609
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Torán, Pere
  • Cusi, Kenneth|||0000-0002-8629-418X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dysglycemia in young women attenuates the protective effect against fatty liver disease

  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Pera, Guillem|||0000-0003-3188-7268
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Expósito, Carmen|||0000-0002-9246-3779
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Sexual dimorphism has been reported in non-alcoholic fatty liver disease (NAFLD), similar to the sex differences evident with cardiovascular disease. Type 2 diabetes mellitus (T2D) significantly increases the risk and severity of NAFLD, but there is scarce information on whether T2D or altered glucose metabolism can modify the prevalence of NAFLD in men and women of reproductive age. To investigate the relationship between age, sex and NAFLD in subjects with and without dysglycemia. We analyzed 2,790 patients. NAFLD was characterized using established diagnostic criteria: one or more positive results on the fatty liver index and hepatic ultrasound. Liver fibrosis (liver stiffness measurement [LSM] ≥8.0 kPa) was assessed by Fibroscan ®. For analysis purposes, we included both T2D and prediabetes under the predefined condition of dysglycemia. The global prevalence of NAFLD was higher in men than in women (50% and 34%; P<0.001), and the prevalence increased with age in both sexes. Older women (≥ 50 years) had a higher prevalence than younger women (<50 years), both in the overall cohort and in non-dysglycemic subjects. In dysglycemic subjects, the prevalence of NAFLD was slightly higher in men (68% vs 61%, p=0.021); in younger subjects, there were no differences in the prevalence of NAFLD between men and women (68% vs 64%, respectively; p=0.635). We found an interaction between dysglycemia and female sex (odds ratio [OR] 1.6 95% confidence interval [CI] 1.0-2.4, p=0.030), and between and age ≥50 years (OR 0.6, 95% CI 0.3-1.0, p=0.046). The global prevalence of LSM ≥8.0 kPa was higher in men compared with women (8% vs 4%; p< 0.001). This prevalence increased with age, mainly in men. We did not find any association between liver fibrosis and age and gender. While the global prevalence of NAFLD is higher in men than in women across all ages, younger women with dysglycemia have a similar risk of developing NAFLD as men of a similar age. Therefore, the presence of dysglycemia may erase the protective effect of female sex against fatty liver disease.